Quarterly report pursuant to Section 13 or 15(d)

Basis of Presentation and Significant Accounting Policies (Narrative) (Details)

v3.19.1
Basis of Presentation and Significant Accounting Policies (Narrative) (Details) - USD ($)
1 Months Ended 3 Months Ended
Oct. 31, 2017
May 31, 2017
May 31, 2016
Mar. 31, 2019
Mar. 31, 2018
Dec. 31, 2018
Oct. 31, 2018
Noncontrolling Interest [Line Items]              
Accumulated deficit       $ 90,295,656   $ 84,580,180  
Net loss       5,819,081 $ 3,528,227    
Cash and cash equivalents       17,896,821   $ 22,154,251  
Revenue       701,062 752,527    
Unearned revenue liability balance       8,000,000      
Proceeds from deferred revenue       300,000      
Operating lease right-of-use assets       520,399      
Operating lease liabilities       528,253      
Understatement of income tax benefit due to immaterial error correction         205,000    
Income tax benefit       45,178 (205,000)    
Grant Revenue [Member]              
Noncontrolling Interest [Line Items]              
Revenue       $ 700,000 $ 800,000    
Pelican Therapeutics, Inc. [Member]              
Noncontrolling Interest [Line Items]              
Percentage of voting interests acquired in acquisition       85.00%   85.00% 85.00%
Amount awarded from CPRIT grant     $ 15,200,000        
Pelican Therapeutics, Inc. [Member] | Grant Revenue [Member] | Second tranche [Member]              
Noncontrolling Interest [Line Items]              
Revenue $ 6,500,000            
Pelican Therapeutics, Inc. [Member] | Grant Revenue [Member] | First tranche [Member]              
Noncontrolling Interest [Line Items]              
Revenue   $ 1,800,000          
Agreement with City of San Antonio [Member]              
Noncontrolling Interest [Line Items]              
Amount awarded from economic development grant       $ 200,000